Androgen Effects on the Reproductive Neuroendocrine Axis: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Androgen Effects on the Reproductive Neuroendocrine Axis (NCT06450405), a non-randomized phase 4 study. The primary outcome is Evidence of Luteal Activity (ELA).

2. Clinical Question

3. Trial Design

The registry classifies this as a Phase 4, nonrandomized, unmasked, parallel-group study. Its listed groups were transgender men, non-binary people, and non-gender-conforming people initiating testosterone replacement therapy, and a control group of cisgender females. The intervention was Testosterone Cypionate 50 MG/ML Injectable Solution. The record specifically cautions that the arms are not a like-for-like control comparison, a point that limits how a between-group contrast could be interpreted even if outcome data were available.

Enrollment is recorded as 2. The record states that the sponsor terminated grant funding before any data beyond names and signatures on consent forms were collected. It further states that there are no data to analyze and that no data will be analyzed in the future. The study status is TERMINATED. Its start date and primary completion date are both recorded as 2025-02-26.

The planned timeframe for the primary endpoint was through study completion, described as an average of 7 months. That timeframe is not evidence that participants were followed for that duration; the record reports that outcome data were not collected. The registry lists serum reproductive hormone evaluation as a secondary outcome and records 4 outcome measures, but reports no analyses. It does not report further details of the protocol, participant follow-up, treatment administration, or statistical analysis plan.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The study sponsor terminated the grant funding before any data, besides names and signatures on consent forms, were collected. There are no data to analyze. No data will be analyzed in the future.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The study terminated before enrollment of TGM initiating TRT. Two CGF participants signed the consent form, but did not provide any demographic information. The only data we collected were name and signature. No data were analyzed. No data will be analyzed in the future. The enrollees would have been scheduled for study visits a week or two after signing the consent form.

6. Primary Endpoint

The registry lists the primary outcome as Evidence of Luteal Activity (ELA), measured over Through study completion, an average of 7 months..

The primary endpoint is Evidence of Luteal Activity (ELA). The registry defines ELA as a serum progesterone level above 3 ng/mL in transgender men initiating testosterone replacement therapy. The intended measure is therefore a biochemical indicator, based on serum progesterone, rather than a symptom report or a direct measurement of every component of reproductive neuroendocrine function.

In general, a prespecified endpoint gives a study a defined outcome to measure against its research question. A laboratory threshold can make an outcome operational: observations are classified according to whether the stated threshold is met. That definition alone does not establish how often the endpoint occurred or whether an intervention changed its frequency. Those conclusions require collected measurements and an analysis appropriate to the study design.

The registry lists a timeframe of through study completion, an average of 7 months. However, it also states that grant funding was terminated before outcome data were collected. No progesterone measurements, endpoint classifications, or summary statistics are reported. The description does not specify the timing or frequency of blood sampling, nor does it detail how observations would have been handled if measurements were unavailable or did not fit a simple classification. These procedural details are not reported in the registry record.

The endpoint definition is stated for the group initiating testosterone replacement therapy. The record does not explain whether, or how, ELA was to be defined and compared in the cisgender female control group. As a result, the endpoint description does not establish a complete comparative estimand. Without observations, neither the frequency of ELA in the initiating group nor a contrast with the control group can be estimated.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies a nonrandomized, unmasked, parallel-group design, but reports no completed statistical analyses. The following explanations describe general statistical principles relevant to interpreting this design; they are not a description of analyses performed in the study. No statistical analysis plan is reported in the registry record.

What does nonrandomized allocation imply?

In general, random allocation helps balance measured and unmeasured baseline characteristics across groups in expectation. In a nonrandomized study, group membership may be associated with characteristics that also relate to the outcome. A crude group contrast can therefore combine an intervention-related difference with pre-existing differences between participants. Statistical adjustment can sometimes address measured differences, but it cannot automatically remove bias from unmeasured factors or correct a poor comparison. The registry itself cautions that these arms are not a like-for-like control comparison. It does not report how group comparability would have been assessed or which covariates might have been included in an analysis.

What would an endpoint comparison require?

The primary outcome is defined as ELA based on a serum progesterone threshold. In general, a binary endpoint analysis needs both the number of participants meeting the definition and the number of evaluable participants in each group. A comparative analysis would then estimate a contrast between groups, with uncertainty quantified using a method suited to the design and data. None of the required endpoint counts or comparative estimates is reported. The registry's endpoint definition and planned timeframe do not substitute for observed values.

What do estimates and confidence intervals convey?

In general, an effect estimate describes the size and direction of a specified contrast, while a confidence interval conveys uncertainty around that estimate under the chosen model and its assumptions. A narrow interval indicates greater statistical precision than a wide interval, but precision does not resolve bias in a nonrandomized comparison. An interval that includes values compatible with different conclusions may leave the evidence inconclusive. These concepts require an actual estimate and data; there is no estimate or confidence interval to interpret for this study.

What is the role of a significance test?

In general, a significance test evaluates observed data under a null hypothesis and a specified statistical model. A p-value is not the probability that the null hypothesis is true, and it does not measure the size or practical importance of an effect. Its interpretation depends on the endpoint, analysis population, model, and any multiplicity strategy. No test statistic or p-value is reported in the registry record, and none can be reconstructed from the endpoint description or the enrollment entry.

Why does sample size matter?

In general, the amount of information available affects the precision of estimates and the ability to distinguish an effect from random variation. Planning a study requires assumptions about the target effect, outcome variability or event frequency, chosen error rates, allocation, and analysis. Those planning inputs are different from observed results. A sample-size calculation cannot supply missing outcome data, and a planning calculation based on an observed effect would require an observed effect to begin with. Here the registry reports no outcome measurements or analyses, so there is no trial-derived effect estimate to interpret or use as an empirical basis for planning.

Enrollment alone is not enough to determine the precision of an outcome estimate. The record reports enrollment of 2, but it also states that outcome data were not collected. There is consequently no analyzable endpoint count, no observed group-specific result, and no basis for calculating statistical power from trial outcomes. Any planning illustration should not be read as observed power or as evidence that the study detected or excluded an effect.

How should the parallel groups be interpreted?

In general, a parallel-group design follows distinct groups under their assigned or naturally occurring exposures and compares outcomes between them. With nonrandomized groups, a comparison is most informative when the groups are sufficiently comparable and the analysis addresses relevant differences. The registry does not describe such an analysis, and expressly warns that the groups are not a like-for-like control comparison. No outcome data are available to support either an unadjusted or adjusted contrast.

The study is also unmasked according to the registry. In general, lack of masking can affect measurement or reporting when outcomes involve judgment or participant reports. A serum laboratory measure may be less dependent on subjective assessment than some outcomes, but collection procedures and laboratory handling still matter. The record does not report these procedures, so no study-specific assessment of measurement bias can be made.

These statistical concepts clarify what would ordinarily be needed to interpret a comparative clinical study; they do not create results where none were collected. For this record, the decisive limitation is the absence of outcome data, followed by the nonrandomized, non-like-for-like comparison that would have required careful interpretation even if measurements had been available.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists serum reproductive hormone evaluation as a secondary outcome and records 4 outcome measures, but it reports no analyses. It does not describe a prespecified hierarchy of outcomes, a multiplicity adjustment, or a strategy for choosing among several statistical tests. Such details are not reported in the registry record. Because no outcome data were collected, there are no reported endpoint-specific estimates or tests whose multiplicity can be evaluated.

In general, testing multiple outcomes or making multiple comparisons can increase the chance of a false-positive finding if each test is interpreted without regard to the others. A prespecified analysis plan can clarify which outcomes are primary, how secondary outcomes will be handled, and whether an adjustment or hierarchical approach is intended. These methods address interpretive risks; they cannot compensate for missing observations. The record does not state what multiplicity approach would have been used.

The registry explicitly says that no data beyond names and signatures on consent forms were collected. This is not a case in which outcome data are reported with some measurements missing: the record says there are no data to analyze and that no future analyses will be conducted. It therefore provides no information about missing outcome counts, reasons for missingness, or any imputation or sensitivity analysis. Those details are not reported in the registry record.

Analysis populations are also not described. The record does not report an intention-to-treat, per-protocol, or other analysis population, nor does it state how participants would have been included in an endpoint analysis. The enrollment entry of 2 cannot establish an outcome-analysis denominator given the explicit statement that outcome data were not collected. As a result, neither the handling of missing data nor the relationship between enrolled participants and any analytic population can be assessed.

11. What the Result Does, and Does Not, Mean

The registry record establishes that a study was planned to examine androgen effects on the reproductive neuroendocrine axis and that its primary endpoint was defined using serum progesterone. It also establishes that the study was terminated before outcome data were collected. The record therefore documents a research question and an endpoint definition, but not an empirical answer to that question.

It does not show whether ELA occurred, how often it might have occurred, or whether the groups differed. It does not establish a beneficial, harmful, or null effect of testosterone, and it does not quantify uncertainty around any effect. The absence of results must not be mistaken for evidence that the intervention has no effect or that the groups have equivalent outcomes. There are no observations from which either conclusion could be drawn.

The record lists 0 events across the adverse-event categories for both groups. In the context of the stated absence of collected data, these entries do not establish that no adverse events occurred. They cannot serve as a safety comparison or as reassurance about the frequency of events. No safety analyses are reported.

In general, a clinical study's result depends on the observed data, the comparison being estimated, and the assumptions of the analysis. Here, the groups were nonrandomized, and the registry warns that they are not a like-for-like control comparison. That design feature would have required caution in any interpretation of group differences. But there are no outcome measurements to which that caution can be applied.

The appropriate reading is narrowly statistical: the registry describes a terminated study with no analyzable outcome results. It neither supports nor refutes the underlying biological hypothesis. The record also states that no data will be analyzed in the future, so it does not describe a pending analysis that might later resolve the question.

12. Why This Trial Matters Statistically

This record matters statistically because it distinguishes a study's research question from evidence generated by its data. The study proposed a defined primary endpoint and identified an intervention and control group, but the sponsor terminated grant funding before outcome data were collected. Since no measurements or analyses exist, the registry cannot support an effect estimate, a confidence interval, a significance test, or an estimate of outcome frequency.

The case also illustrates why enrollment is not interchangeable with an analyzable sample. The registry records enrollment of 2, yet states that no outcome data were collected. Enrollment describes the study record, not the number of endpoint observations available for a statistical comparison. Without measurements, there is no basis for assessing precision or deciding whether an observed result is compatible with a range of effects.

Design information remains important even when results are absent. The study was nonrandomized and unmasked, and the record warns that its groups are not a like-for-like control comparison. In general, these features affect how a future or hypothetical group contrast should be interpreted: a difference could reflect group composition as well as exposure, and measurement procedures can matter. Statistical adjustment cannot be assumed to solve those issues, particularly when the registry does not report an adjustment plan.

Finally, the record underscores that zero entries in adverse-event categories do not become meaningful safety evidence when the same record says no outcome data were collected. Correct interpretation requires attention to what was actually measured, not just the presence of a numerical entry. The statistically responsible conclusion is that the study yielded no analyzable clinical results, while its design and endpoint descriptions remain documented.

13. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most consequential limitation is explicit: the sponsor terminated grant funding before any data beyond names and signatures on consent forms were collected. The registry states that there are no data to analyze and that no data will be analyzed in the future. Accordingly, the primary endpoint and secondary outcome have no reported observations, and no treatment-effect estimate or uncertainty measure is available.

The study is listed as nonrandomized, and the registry cautions that the arms are not a like-for-like control comparison. This leaves potential group differences that could complicate interpretation of any hypothetical contrast. The record does not report participant characteristics or an adjustment strategy. The unmasked design is another relevant feature, but the registry does not describe outcome collection or laboratory procedures sufficiently to assess its effect on measurement.

The registry records enrollment of 2, but gives no analyzable outcome denominator because it reports that outcome data were not collected. It does not provide endpoint frequencies, participant-level observations, follow-up completion, or reasons for any absent measurements. The average 7-month timeframe is a planned endpoint timeframe, not evidence of completed follow-up.

Further details about treatment administration, eligibility, the control group's endpoint definition, analysis populations, missing-data methods, multiplicity handling, and statistical analysis procedures are not reported in the registry record. The adverse-event categories list 0 events, but the lack of collected outcome data means those entries cannot establish that events were absent. Together, these limitations prevent estimates of efficacy, comparative effects, precision, or safety.

14. Related Tutorials

15. Related Statistical Calculators

16. Sources

• ClinicalTrials.gov: Androgen Effects on the Reproductive Neuroendocrine Axis — NCT06450405.
• Registry record last updated 2025-07-22; status last verified 2025-07.
• Results first posted 2025-07-14.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

17. Record Summary

The registry describes a Phase 4, nonrandomized, unmasked, parallel-group study of androgen effects on the reproductive neuroendocrine axis. The listed intervention was Testosterone Cypionate 50 MG/ML Injectable Solution. The groups were people initiating testosterone replacement therapy and a cisgender female control group; the registry cautions that the arms are not a like-for-like control comparison.

The primary endpoint was Evidence of Luteal Activity, defined as serum progesterone above 3 ng/mL in transgender men initiating testosterone replacement therapy, with a timeframe through study completion, an average of 7 months. Enrollment is recorded as 2. The study status is TERMINATED, with start and primary completion dates both recorded as 2025-02-26.

The record states that grant funding ended before outcome data were collected, that there are no data to analyze, and that no data will be analyzed in the future. It lists 4 outcome measures and no analyses. No treatment-effect or safety conclusion can be drawn from the posted results.